CYTOSORBENTS CORPORATION Foreign Income Tax Expense (Benefit), Continuing Operations
CYTOSORBENTS CORPORATION (CTSO) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2022-03-10
- CYTOSORBENTS CORPORATION foreign income tax expense (benefit), continuing operations for fiscal 2021 was $0.00.
- CYTOSORBENTS CORPORATION foreign income tax expense (benefit), continuing operations for fiscal 2020 was $0.00.
- CYTOSORBENTS CORPORATION foreign income tax expense (benefit), continuing operations for fiscal 2019 was $0.00.
- CYTOSORBENTS CORPORATION foreign income tax expense (benefit), continuing operations for fiscal 2018 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-09 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |